Francesco Sclafani1, Sheela Rao2. 1. Department of Medicine, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK. 2. Department of Medicine, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5PT, UK. sheela.rao@rmh.nhs.uk.
Abstract
PURPOSE OF REVIEW: We aim to summarise the available evidence on systemic therapies for advanced anal cancer. RECENT FINDINGS: There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, ever-conducted, randomised trial in the first-line setting, investigation of immunotherapy in the refractory setting and use of comprehensive genomic profiling for a better molecular characterisation of this disease and the identification of novel potential targets. The combination of a platinum agent and a fluoropyrimidine is generally considered the standard first-line treatment. Other cytotoxic agents, especially docetaxel and paclitaxel, have shown activity in both the chemotherapy-naive and chemo-refractory setting and are currently being investigated in clinical trials. Finally, further to the promising results of early clinical trials, immunotherapy with checkpoint inhibitors (i.e. nivolumab and pembrolizumab) is likely to become a standard second-line treatment option.
PURPOSE OF REVIEW: We aim to summarise the available evidence on systemic therapies for advanced anal cancer. RECENT FINDINGS: There is no universal consensus on the management of this condition and the prognosis remains poor. Nevertheless, significant progress has been recently made including completion of the first, ever-conducted, randomised trial in the first-line setting, investigation of immunotherapy in the refractory setting and use of comprehensive genomic profiling for a better molecular characterisation of this disease and the identification of novel potential targets. The combination of a platinum agent and a fluoropyrimidine is generally considered the standard first-line treatment. Other cytotoxic agents, especially docetaxel and paclitaxel, have shown activity in both the chemotherapy-naive and chemo-refractory setting and are currently being investigated in clinical trials. Finally, further to the promising results of early clinical trials, immunotherapy with checkpoint inhibitors (i.e. nivolumab and pembrolizumab) is likely to become a standard second-line treatment option.
Authors: Joseph A Sparano; Jeannette Y Lee; Joel Palefsky; David H Henry; William Wachsman; Lakshmi Rajdev; David Aboulafia; Lee Ratner; Thomas J Fitzgerald; Lisa Kachnic; Ronald Mitsuyasu Journal: J Clin Oncol Date: 2016-12-12 Impact factor: 44.544
Authors: P A Ott; S A Piha-Paul; P Munster; M J Pishvaian; E M J van Brummelen; R B Cohen; C Gomez-Roca; S Ejadi; M Stein; E Chan; M Simonelli; A Morosky; S Saraf; K Emancipator; M Koshiji; J Bennouna Journal: Ann Oncol Date: 2017-05-01 Impact factor: 32.976
Authors: Melanie Demes; Ursula Pession; Jan Jeroch; Falko Schulze; Katrin Eichler; Daniel Martin; Peter Wild; Oliver Waidmann Journal: Oncotarget Date: 2022-09-14
Authors: S Rao; G Anandappa; J Capdevila; L Dahan; L Evesque; S Kim; M P Saunders; D C Gilbert; L H Jensen; E Samalin; K-L Spindler; S Tamberi; A Demols; M G Guren; D Arnold; M Fakih; T Kayyal; M Cornfeld; C Tian; M Catlett; M Smith; J-P Spano Journal: ESMO Open Date: 2022-07-08
Authors: Angélique Saint; Ludovic Evesque; Alexander T Falk; Gérard Cavaglione; Lucile Montagne; Karen Benezery; Eric Francois Journal: Cancer Med Date: 2019-09-16 Impact factor: 4.452